Johnson & Johnson
JNJ153.240USD
-6.600-4.12%
收盘 04/04, 16:00（美东）报价延迟15分钟
368.84B总市值
26.22市盈率 TTM
关于 Johnson & Johnson 公司
强生公司通过其子公司从事医疗保健领域一系列产品的研发、制造和销售。该公司的主要重点是与人类健康和福祉相关的产品。公司通过两个部门运营：创新医学和医疗技术。创新医学部门专注于各种治疗领域，包括免疫学、传染病、神经科学、肿瘤学、肺动脉高压以及心血管和代谢疾病。该部门的产品直接分销给零售商、批发商、分销商、医院和医疗保健专业人员，用于处方用途。医疗技术部门包括用于骨科、外科、介入解决方案、心血管介入和视觉领域的广泛产品组合。医疗技术部门还提供用于冠状动脉疾病 (CAD) 和外周动脉疾病 (PAD) 的商用血管内碎石术 (IVL) 平台。
公司简介
公司代码JNJ
公司名称Johnson & Johnson
上市日期Sep 25, 1944
成立日期1887
CEOMr. Joaquin Boix Duato
员工数量138100
证券类型Ordinary Share
年结日Sep 25
公司地址One Johnson & Johnson Plaza
城市NEW BRUNSWICK
上市交易所NYSE Consolidated
国家United States of America
邮编08933
电话17325242455
网址https://www.jnj.com/
公司代码JNJ
上市日期Sep 25, 1944
成立日期1887
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
-32.09%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
+14.96%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
+4.05K%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
15.54K
+6.62%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resource Officer, Executive Vice President
Chief Human Resource Officer, Executive Vice President
14.12K
+20.79%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
10.90K
+30.72%
Ms. Anne M. Mulcahy
Ms. Anne M. Mulcahy
Independent Director
Independent Director
8.41K
+3.87%
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
-32.09%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
+14.96%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
+4.05K%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
15.54K
+6.62%
收入明细
单位: USD更新时间: 4月2日 周三
单位: USD更新时间: 4月2日 周三
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Oncology-DARZALEX
11.67B
13.14%
Immunology-STELARA
10.36B
11.67%
Interventional Solutions
7.71B
8.68%
Surgery-General
5.36B
6.03%
Surgery-Advanced
4.49B
5.05%
Other
49.24B
55.43%
地区USD
名称
营收
占比
United States
50.30B
56.63%
International
38.52B
43.37%
Europe
20.21B
22.76%
Asia-Pacific, Africa
13.59B
15.30%
Western Hemisphere, excluding U.S.
4.71B
5.31%
业务
地区
业务USD
名称
营收
占比
Oncology-DARZALEX
11.67B
13.14%
Immunology-STELARA
10.36B
11.67%
Interventional Solutions
7.71B
8.68%
Surgery-General
5.36B
6.03%
Surgery-Advanced
4.49B
5.05%
Other
49.24B
55.43%
股东统计
更新时间: 4月4日 周五
更新时间: 4月4日 周五
持股股东
股东类型
持股股东
股东统计
占比
The Vanguard Group, Inc.
9.62%
State Street Global Advisors (US)
5.58%
BlackRock Institutional Trust Company, N.A.
5.39%
Geode Capital Management, L.L.C.
2.39%
State Farm Insurance Companies
1.31%
Other
75.70%
持股股东
股东统计
占比
The Vanguard Group, Inc.
9.62%
State Street Global Advisors (US)
5.58%
BlackRock Institutional Trust Company, N.A.
5.39%
Geode Capital Management, L.L.C.
2.39%
State Farm Insurance Companies
1.31%
Other
75.70%
股东类型
股东统计
占比
Investment Advisor/Hedge Fund
33.36%
Investment Advisor
28.70%
Research Firm
3.01%
Pension Fund
2.28%
Bank and Trust
2.12%
Insurance Company
1.50%
Sovereign Wealth Fund
1.36%
Hedge Fund
0.75%
Foundation
0.43%
Other
26.49%
机构持股
更新时间: 2月20日 周四
更新时间: 2月20日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q1
5849
1.79B
74.14%
+9.27M
2024Q4
5953
1.78B
74.14%
+8.28M
2024Q3
5699
1.77B
73.47%
+2.69M
2024Q2
5691
1.75B
72.75%
+9.12M
2024Q1
5685
1.73B
71.58%
-6.08M
2023Q4
5686
1.72B
71.40%
-7.80M
2023Q3
5524
1.72B
71.21%
-159.24M
2023Q2
5528
1.87B
71.81%
+6.27M
2023Q1
5490
1.85B
71.21%
-28.44M
2022Q4
5447
1.87B
71.55%
+6.54M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
231.82M
9.62%
+1.80M
+0.78%
Dec 31, 2024
State Street Global Advisors (US)
134.46M
5.58%
+210.35K
+0.16%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
130.00M
5.39%
+2.12M
+1.65%
Dec 31, 2024
Geode Capital Management, L.L.C.
57.67M
2.39%
+1.56M
+2.78%
Dec 31, 2024
State Farm Insurance Companies
31.68M
1.31%
--
--
Dec 31, 2024
Norges Bank Investment Management (NBIM)
30.36M
1.26%
+1.26M
+4.34%
Dec 31, 2024
Wellington Management Company, LLP
24.36M
1.01%
+431.20K
+1.80%
Dec 31, 2024
JP Morgan Asset Management
24.04M
1%
+5.40M
+29.00%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
22.91M
0.95%
-654.88K
-2.78%
Dec 31, 2024
BlackRock Asset Management Ireland Limited
19.88M
0.82%
+587.38K
+3.05%
Dec 31, 2024
查看更多
持股ETF
更新时间: 4月2日 周三
更新时间: 4月2日 周三
机构名称
占比
iShares U.S. Pharmaceuticals ETF
24.61%
FT Vest DJIA Dogs 10 Target Income ETF
13.93%
First Trust NASDAQ Pharmaceuticals ETF
8.4%
American Century Focused Large Cap Value ETF
7.72%
VanEck Pharmaceutical ETF
7.37%
Proshares Ultra Health Care
7.32%
Health Care Select Sector SPDR Fund
7.31%
iShares Core High Dividend ETF
7.19%
iShares U.S. Healthcare ETF
7.11%
JPMorgan Healthcare Leaders ETF
6.46%
查看更多
iShares U.S. Pharmaceuticals ETF
占比24.61%
FT Vest DJIA Dogs 10 Target Income ETF
占比13.93%
First Trust NASDAQ Pharmaceuticals ETF
占比8.4%
American Century Focused Large Cap Value ETF
占比7.72%
VanEck Pharmaceutical ETF
占比7.37%
Proshares Ultra Health Care
占比7.32%
Health Care Select Sector SPDR Fund
占比7.31%
iShares Core High Dividend ETF
占比7.19%
iShares U.S. Healthcare ETF
占比7.11%
JPMorgan Healthcare Leaders ETF
占比6.46%
分红派息
近5年累计派现
56.79B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Jan 02, 2025
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025
Feb 18, 2025
Mar 04, 2025
Feb 18, 2025
Oct 15, 2024
JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 10, 2024
Nov 26, 2024
Jul 17, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024
Aug 27, 2024
Sep 10, 2024
Aug 27, 2024
Apr 16, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024
May 21, 2024
Jun 04, 2024
May 20, 2024
Jan 02, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024
Feb 20, 2024
Mar 05, 2024
Feb 16, 2024
Oct 19, 2023
JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023
Nov 21, 2023
Dec 05, 2023
Nov 20, 2023
Jul 20, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023
Aug 28, 2023
Sep 07, 2023
Aug 25, 2023
Apr 18, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023
May 23, 2023
Jun 06, 2023
May 22, 2023
Jan 03, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023
Feb 21, 2023
Mar 07, 2023
Feb 17, 2023
Oct 18, 2022
JNJ.NB Final Cash Dividend of gross USD 1.13 paid on Dec 06, 2022 going ex on Nov 21, 2022
Nov 22, 2022
Dec 06, 2022
Nov 21, 2022
查看更多
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据